Isatuximab in Combination With Novel Agents

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

What's the purpose of the trial?

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Trial status

Accepting patients

Phase

Phase 1/2

Enrollment

197

Last Updated

2 weeks ago

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Belantamab Mafodotin
Belumosudil mesylate
Dexamethasone
Evorpacept
Isatuximab
Pegenzileukin (SAR444245)
Pomalidomide
SAR439459

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Accepting patients

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.